Can-Fite BioPharma Ltd.

CANF

Exchange: NYSE
Industry: Pharmaceutical Preparations
SEC CIK: 0001536196

SEC filings (opens in a new tab)

No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.

Q2 2023 vs. Q1 2023

How the institutions holding Can-Fite BioPharma Ltd. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023 All holders in Q1 2023

13F holders of CANF: Q1 2023 compared with Q2 2023
Measure	Q1 2023	Q2 2023	Change
Holders	9	7	−2
Shares	368.4K	54.6K	−313.8K (−85.2%)
Value	$843.5K	$167.8K	−$675.7K (−80.1%)

New holders (1)

Institutions that held Can-Fite BioPharma Ltd. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to CANF in Q2 2023
Institution	Shares	Value	% of portfolio
Rhumbline Advisers	17,102	$52.5K	0.00%

Sold out (3)

Institutions that held Can-Fite BioPharma Ltd. at the end of Q1 2023 and filed for Q2 2023 without it.

Institutions that sold out of CANF in Q2 2023
Institution	Shares, Q1 2023	Value, Q1 2023
Armistice Capital, LLC	330,000	$755.7K
UBS Group AG	714	$1.64K
JPMorgan Chase & Co	100	$0